Orchard Therapeutics Receives Innovation Passport for Gene Therapy OTL-201 Targeting Rare Sanfilippo Syndrome
Key Insights
Orchard Therapeutics (search) has been awarded Innovation Passport designation for OTL-201, an investigational gene therapy for mucopolysaccharidosis type IIIA (search) (MPS-IIIA (search)), under the UK's refreshed Innovative Licensing and Access Pathway.
OTL-201 is one of only three investigational therapies initially granted this designation, which aims to accelerate development timelines and patient access to transformative medicines addressing significant medical needs.
MPS-IIIA (search) is a rare, fatal neurometabolic disorder (search) affecting approximately one in 100,000 live births, with children rarely surviving past adolescence and no currently approved disease-modifying therapies available.
Orchard Therapeutics (search), a Kyowa Kirin company, has received Innovation Passport designation for OTL-201, an investigational haemopoietic stem cell (HSC) gene therapy targeting mucopolysaccharidosis type IIIA (search) (MPS-IIIA (search)). The designation was granted under the UK's recently refreshed Innovative Licensing and Access Pathway (ILAP), which provides an integrated platform for collaboration between developers, the Medicines and Healthcare products Regulatory Agency (MHRA), health technology assessment authorities, and the National Health Service.
OTL-201 represents one of only three investigational therapies initially awarded Innovation Passport designation under the refreshed ILAP, which focuses on potentially transformative medicines addressing significant medical needs.
Addressing a Critical Unmet Medical Need
MPS-IIIA (search), also known as Sanfilippo syndrome type A (search), is a rare, fatal neurometabolic disorder (search) caused by mutations in both copies of the N-sulphoglucosamine sulphohydrolase (search) (SGSH (search)) gene. This genetic defect impairs production of the functional SGSH enzyme needed to break down heparan sulfate, leading to toxic accumulation in the body, including the central nervous system.
The disease occurs in approximately one in every 100,000 live births and results in neurodegenerative disease (search) characterized by progressive loss of cognitive and motor function. Children with MPS-IIIA (search) rarely survive past adolescence, with life expectancy estimated between 10-25 years (median 14.5 years). Currently, no approved disease-modifying therapies exist to treat this devastating condition.
Gene Therapy Approach
OTL-201 is an investigational ex vivo autologous HSC gene therapy that uses a modified virus to insert a functional copy of the SGSH (search) gene into a patient's harvested HSCs. The approach involves genetically modifying a patient's own blood stem cells outside the body before reinfusion, with the goal of correcting the underlying cause of disease with a single treatment.
The therapy has already received multiple regulatory designations, including rare paediatric disease designation and orphan drug designation from the FDA, orphan designation from the EMA, and now Innovation Passport designation under the ILAP in the UK. OTL-201 is currently being evaluated in an ongoing investigator-sponsored proof-of-concept clinical trial in the UK (NCT04201405).
Accelerated Development Pathway
The Innovation Passport serves as the entry point for companies to participate in ILAP, which was first launched in January 2021 and refreshed in January 2025. The pathway is described as the only end-to-end access pathway in the world where multi-stakeholder engagement is established at an early stage of clinical development.
"Being selected as one of the first investigational therapies granted the Innovation Passport designation under the new ILAP is further validation that the life-changing value OTL-201 has the potential to provide children with MPS-IIIA (search) and their families," said Andrew Olaye, general manager, UK and Ireland at Orchard Therapeutics (search). "We commend the MHRA for introducing the designation and addressing the need to speed development timelines and quicken access to innovative new treatment options for patients in need."
The refreshed ILAP features enhanced input and interactions with the MHRA and ILAP partners, including the All Wales Therapeutics and Toxicology Centre, the National Institute for Health and Care Excellence, the Scottish Medicines Consortium, and the NHS. Benefits include access to services supporting clinical development, market access, and health system adoption, reducing product development duration and facilitating rapid access to the UK market.
Company Background
Orchard Therapeutics (search), founded in 2015, is a global gene therapy leader focused on HSC gene therapy development. The company's roots trace back to early research and clinical developments in HSC gene therapy, with the team playing a central role in evolving this technology from scientific concept to potential clinical reality. Orchard is advancing a portfolio of HSC gene therapies designed to address serious diseases with immense patient burden and limited treatment options.